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Introduction: There is high incidence of SCD in the early period following STEMI. We
compared the temporal patterns and predictors of SCD amongst patients with LVEF 35%
and LVEF >35%.
Methods: Data from STEMI patients was prospectively collected. SCD cases formed the
study cohort and were categorized into 2 groups based on their LV function.
Results: There were 929 patients (mean age 55 ± 17 years) with a follow up of 41 ± 16
months. 154 pts (16.6%) had LVEF 35% (Group A, LVEF-29.9% ± 6%) and 775 pts had LVEF
>35% (Group B, LVEF e 49% ± 14%). The two groups were similar with respect to sex dis-
tribution, age, prevalence of hypertension, and mean period of presentation. They differed
in incidence of anterior wall MI (77.2% vs 55%), reperfusion (69% vs. 75%), prevalence of
diabetes (50.6% vs 42%), and medication non-compliance (34% vs. 13%). The total SCD was
78 [Gp A, 25 (16.2%); Gp B, 53 (6.8%); p < 0.001]. The temporal cumulative SCD related
mortality in the 2 groups was 1st month (8% vs. 4% p ¼ 0.075), 3 months (14% vs. 5%,
p < 0.001), 6 months (17% vs. 5%, p < 0.001), 1 year (18% vs. 6%, p < 0.001), at end of follow up
(27% vs. 8%, p < 0.001). Multivariate predictors of SCD were medication compliance in the
first month, and severe LV dysfunction with medication compliance beyond 1st month.
Conclusion: The incidence of SCD is high in first month after STEMI, irrespective of LV
function. The number of SCD is higher in Group B patients. Algorithms to assess risk of SCD
in early post STEMI period are urgently needed.
Copyright © 2014, Cardiological Society of India. All rights reserved.0.
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ociety of India. All rights reserved.
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Acute myocardial infarction (MI) constitutes the commonest
cardiovascular substrate for sudden cardiac death (SCD). It
has been observed that there is a clustering of SCD cases in the
early post MI period and we found in an earlier study that a
significant proportion of SCD occur in the first month
following ST elevation myocardial infarction (STEMI) event.1
This report is designed to compare the temporal patterns
and predictors of sudden death amongst the STEMI patients
with and without severe LV dysfunction.2. Methods
The patient population was obtained from a large tertiary
cardiac care centre. The methodology and patient character-
istics have been previously described.1 Briefly, patients
admitted with acute STEMI were entered into a predesigned
data base and follow up data was collected over a 3 year
period. Deaths were classified as cardiovascular deaths
(CVDs), non-cardiovascular or unclassifiable. CVDs were
further classified as sudden or non-sudden. Classification of
deaths was done by two independent monitors and resolved
by an adjudicator in case of conflict. This study was approved
by the institutional ethics committee.Table 1 e Demographic characteristics (n ¼ 929).
Characteristic Group A Group B p Value3. Definitions
For the purpose of this studywe used the following definitions
which were used in our earlier study.1
1. CVD: Deaths related to heart failure, ischemia, recurrent
infarction, arrhythmic and non-arrhythmic sudden
deaths, and cerebrovascular accidents.
2. SCD: CVD was defined as sudden if it was: (A) a witnessed
death that occurred within 60 min from the onset of new
symptoms unless a cause other than cardiac was obvious;
(B) an unwitnessed death (<24 h) in the absence of pre-
existing progressive circulatory failure or other causes of
death; or (C) death during attempted resuscitation.
3. Severe LVDysfunction: LV ejection fraction35%, assessed
by 2D Echocardiogram by standard methods.
4. Compliance with medications: Patients who took at least
beta blockers and antiplatelet drugs.(n ¼ 154) (n ¼ 775)
Male:Female 127:27 638:137 0.3331
Mean age 57.92 ± 20 yrs 54.95 ± 20 yrs 0.0534
Diabetes 80 (50.6%) 325 (42%) 0.0111
Hypertension 88 (55.7%) 401 (52%) 0.1103
Reperfused 106 (69%) 584 (75%) 0.0454
Revascularized 56 (36%) 309 (40%) 0.2164
Anterior MI 122 (77.2%) 428 (55%) <0.0001
Time of presentation
(in hours)
4.46 ± 4 3.96 ± 3 0.0815
Mean LVEF 29.9% ± 6% 49% ± 14% <0.0001
Non-compliance
with evidence
based medication
53 (34.4%) 104 (13.4%) <0.00014. Statistics
Statistical analyses were performed using MedCalc for Win-
dows, V.12 e 1993e2011 (MedCalc Software, Mariakerke,
Belgium). Discrete variables were presented in percent and
continuous variables as mean ± 6 standard deviation (SD).
Chi-square test was done to compare discrete variables and t-
test was done to compare continuous variables. Cumulative
event rates were calculated with the use of the KaplaneMeier
method. Multivariate analysis was performed using the Coxproportional-hazards regression. Event times for all patients
were measured from the time of admission.5. Results
There were 929 patients (765male and 164 female) with STEMI
followed up for a mean period of 41 ± 16 months. Their mean
age was 55 ± 17 years (Female: 60 ± 11 years; Male: 54 ± 18
years). Patients were categorized into 2 groups based on their
pre-discharge LV function assessment. Patients with LV
ejection fraction (LVEF) 35% (n ¼ 154) constituted group A,
while those with LVEF >35% (n ¼ 775) were included in group
B. The demographic characteristics of these two cohorts are
summarized in Table 1. The two groupswere comparable with
respect to age and sex distribution and presentation time, but
the proportion of anterior wall MI and diabetes mellitus,
incidence of reperfusion were higher in cohort A. Non-
compliance with evidence based medication was signifi-
cantly higher in cohort A compared to cohort B (34%& vs. 13%,
p < 0.001).
At the end of follow up the total mortality was 62 (40.3%) in
group A and 97 (12.5%) in group B (p  0.001). Of these, the
number of patients who were adjudicated to have died due to
SCD were 25 (16.2%) and 53 (6.8%) respectively (p  0.001). The
temporal profile of SCD is shown in Fig. 1. The cumulative SCD
related mortality in group A was 12 (8%) in the 1st month, 15
(14%) in the first 3 months, 17 (17%) in the 1st 6 months, 18
(18%) in the first year and 25 (27%) at the end of follow up. The
corresponding numbers in group B were 34(4%), 34(5%),
36(5%), 42(6%) and 53 (8%) respectively [p ¼ 0.075, <0.001,
<0.001, <0.001, <0.001 respectively.]. In both the groups most
of the SCD cases occurred in the first month. This is apparent
by the fact that 12 out of total 25 SCD in Group A and 34 out of
total 53 SCD in Group B occurred in this period (p ¼ 0.186).
The effect of various factors influencing the occurrence of
SCDwas analyzed over time. Table 2A and B show the effect of
predictive factors in the first month and beyond following
STEMI. During the first month, univariate analysis demon-
strated LV dysfunction, diabetes mellitus, absence of reper-
fusion and revascularization, non-compliance with
Fig. 1 e Kaplan-Meyer survival curves of sudden cardiac death free survival in Group A (LVEF ≤ 35%) compared with Group B
(LVEF > 35%) show that the curves are parallel till the first month following which they start diverging. The right panel is a
magnified version of the initial portion of the graph. This figure shows that there is no difference in the occurrence of SCD
between the two cohorts in the first month after STEMI (p ¼ 0.37), while the incidence increases in the Group A after this
period and continues till end of follow up (p < 0.0001).
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multivariate analysis revealed only non-compliance with
medication to be a significant predictor of SCD. In contrast,
after 1 month, univariate predictors of SCD were presence of
severe LV dysfunction, absence of reperfusion and revascu-
larization, female sex and lack of compliance to evidence
based medication. Multivariate analysis narrowed these pre-
dictors to severe LV dysfunction and lack of compliance to
medications.6. Discussion
SCD constitutes 10% of total mortality in India with acute
coronary events being the commonest etiology.2 It remains
the most unpredictable catastrophic clinical event in post
STEMI patients. The risk is high in the initial period following
acute MI but continues to exist in patients with remoteMI and
LV dysfunction.While implantation of ICD has been proven to
provide safety from SCD in the latter group of patients, this
strategy has not been found useful in tackling the arrhythmic
mortality in the early period. This inference was drawn from
the DINAMIT trial where ICD in early post MI period (6e40
days) in patients with LVEF 35% and autonomic impairment
showed no mortality benefit at 1 year (7.5% vs. 6.9%).3 It was
found that non-arrhythmic deaths resulting from worseningTable 2A e Predictors of sudden cardiac death in the first mon
Predictor b SE
LVEF  35% 0.4379 0.3446
Non-compliance with evidence based
medications
5.5381 0.7365
Absence of reperfusion or
revascularization
0.1955 0.3031
Female sex 0.2834 0.3328ventricular function from increased shocks in addition to
cardiac rupture and pump failure negated the beneficial effect
of defibrillators. It is to be highlighted that this and other ICD
studies focused on the presence of severe LV dysfunction for
risk stratification.
This study has 2 important observations. Firstly, most of
the SCD cases post STEMI occur in the 1st month and pres-
ence of severe LV dysfunction alone cannot be relied upon to
stratify risk in this period. This is shown by the fact that in the
first month, SCD related mortality was statistically not
different in the 2 groups. Secondly, the SCD burden is higher
in the groupwith better LV function, as seen by the fact that in
this period 34 out of 46 SCD occurred in this group. Being
numerically the larger group, the SCD numbers are logically
more in this cohort, though the proportion of SCD in patients
with LVEF 35% is higher. Both these facts have significant
clinical implications. It has been shown in our earlier study
and by other groups thatmortality and SCD aremore common
after MI in the first few months. Data from the western world
show that early revascularization particularly by primary PCI
and use of evidence based medications have contributed to
progressive decline in mortality during this period.4e12 Un-
fortunately these positive trends have not percolated to India
and other similar nations.1 This is also evident in our results
which show that in the early post MI period compliance to
evidence based medications was the only factor byth after STEMI multivariate analysis.
Wald Exp(b) 95% CI of Exp(b) p
1.6150 0.6454 0.3296e1.2637 0.2038
56.5405 254.1959 60.4551e1068.8184 <0.0001
0.4158 1.2159 0.6732e2.1959 0.5191
0.7247 1.3276 0.6937e2.5406 0.3946
Table 2B e Predictors of sudden cardiac death beyond one month following STEMI multivariate analysis.
Predictor b SE Wald Exp(b) 95% CI of Exp(b) p
LVEF  35% 1.5061 0.3677 16.7792 4.5091 2.2015e9.2356 <0.0001
Non-compliance with evidence based
medications
3.6924 0.7629 23.4230 40.1420 9.0675e177.7106 <0.0001
Absence of reperfusion or
revascularization
0.6306 0.3863 2.6648 1.8788 0.8845e3.9906 0.1026
Female sex 0.3077 0.4368 0.4960 1.3602 0.5803e3.1884 0.4813
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predictably severe LV dysfunction was the only factor influ-
encing occurrence of SCD. These results demonstrate that
focusing on LV function alone in the early post MI period may
result in under recognizing a number of potential SCD cases.
The number of SCD in the group B is not insignificant and
there exists a strong case for evolving risk stratification stra-
tegies for patientswith relatively preserved LV function in this
period. There has been active work in this area and we may
expect robust SCD risk predictors in the early post MI popu-
lation in the near future. Zaman etal used electrophysiological
studies following primary PCI to recommend ICD implanta-
tion. Theywere successful in showing amortality reduction at
12 months by employing this strategy in a select subgroup of
patients with LVEF <40%. This study however did not include
patients with better LV function.13 Echocardiographic pa-
rameters like global longitudinal strain have been explored as
markers of SCD in both preserved and impaired LV function
and this parameter did not only risk stratify the patients with
good LV function for SCD risk, but also identified patients with
significant LV dysfunction who were not at high SCD risk.14
There is data showing value of some cardiac biomarkers in
predicting myocardial fibrosis and mortality in heart failure
population. These and other biomarkers may be investigated
as components of risk stratification algorithms.15 In the pre-
sent times where extended loop recorders (ELR) are available
which can non invasively record cardiac rhythms, it may be
useful to employ them in early post MI period. There could be
increased role for external wearable defibrillators in select
group of patients. Another clinically relevant observation that
emerges in this report is the consistent correlation of SCD and
compliance with evidence based medications throughout the
study period. This fact assumes importance when seen in the
background of PURE study where there was gross under usage
of evidence based medications for secondary prophylaxis in
patients from low income countries.16 There is hence
considerable wisdom in prioritizing health care resources to
ensure early reperfusion and effective compliance with
medications. This would certainly be a cost effective strategy
to combat SCD in India.7. Limitations of the study
This is a single center study with relatively small number of
SCD. The follow up was not regulated by a protocol. However,
this presents a real life practice scenario which is represen-
tative of contemporary Indian practice.8. Conclusions
Patients with STEMI are at increased risk of SCD in the 1st
month irrespective of presence of severe LV dysfunction and
in terms of absolute numbers, SCD is higher in patients with
preserved LV function. There is a need to evolve risk stratifi-
cation algorithms beyond LV function this period.Conflicts of interest
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